Tracers / [177Lu]Lu-P17-087
[177Lu]Lu-P17-087
Also written as [177Lu]Lu-P17-087; [Lu-177]Lu-P17-087
- Radionuclide
- Lu-177 t½ 9585 min
- Modality
- Therapy
- Production route
- —
- Stage
- investigational
- Syntheses indexed
- 3
What it is
- Compound class
- PSMA-targeted small-molecule radioligand
- Target / mechanism
- Prostate specific membrane antigen (PSMA) PMID 41249585
- Clinical application
- Metastatic castrate resistant prostate cancer (mCRPC) PMID 41249585
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| MiniLu | custom manifold | none | ~95% | ~99% | P17-087 Five Eleven Pharma | 41249585 2025 EJNMMI Radiopharm Chem a new cassette-based, radiosynthesis platform named MiniLu™ — A final product yield (activity in dose vial / starting Lu-177 activity) of ~ 95% was achieved after formulation with L-ascorbate and gentisic acid |
| MiniLu in-house | custom manifold | none | ~95% | 99% | P17-087 Five Eleven Pharma | 41249585 2025 EJNMMI Radiopharm Chem a custom-made, cassette-based box named MiniLu™ — A final product yield (activity in dose vial / starting Lu-177 activity) of ~ 95% was achieved after formulation with L-ascorbate and gentisic acid (15 mL) and sterile filtration using MiniLu™ and the simulated high activity conditions for both compounds. |
| — | — | — | — | — | — | 42418373 2026 J Med Chem |
Need this precursor?We can point you to suppliers for [177Lu]Lu-P17-087, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Lu-177 preparation -> Lu-177m content (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [177Lu]Lu-P17-087.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with Lu-177. Stage set/updated at stage 23 from PMID 41249585: '[177Lu]Lu-P17-087 and [177Lu]Lu-P17-088 are new prostate specific membrane antigen (PSMA) targeted drugs under clinical investigation in China.'.